ライフサイエンスコーパス: phase I

1 ion (0.25 mg once daily to 1 mg twice daily, phase I).

2 rmacokinetic evaluation was performed during phase I.

3 orrelation becomes stronger in Phase II than Phase I.

4 Gas-phase I(2) was measured directly above the surface of li

5 ember 2017, with the following study design: phase I, 2-minute resting state at baseline (room air);

6 otal calculated thermal conductivity of this phase is 220 Wm(-1) K(-1) with the EES reduction not exc

7 The hardness of the Zr(0.5)Y(0.5)B(12) phase is 47.6 +/- 1.7 GPa at 0.49 N load, which is ~17%

8 In phase I, 487 features were derived from the basic set of

9 e fell from 195 to 75 cases per 1,000 during phase I (61.5% reduction) and to 67 per 1,000 during pha

10 of stable compositions and obtaining a pure phase is a challenge.

11 ir binary halides and confirm that the alpha-phase is a high temperature polymorph, metastable under

12 e protected from decay whenever the relative phase is a multiple of pai.

13 Our results show that the cubic phase is a suitable alternative to generate a high free

14 separation into solute-rich and solute-poor phases is a fundamental step leading to the nucleation o

15 Dissolution of Fe(III) phases is a key process in making iron available to biot

16 Dissolution of iron(III)phases is a key process in soils, surface waters, and th

17 One of the phases is a nematic liquid crystal with a highly anisotr

18 reduction on change from cubic to tetragonal phase is about 9%.

19 Xi position in S phase is also corrupted in cells adapted to long-term cu

20 This lytic phase is also essential for EBV to cause infectious mono

21 Because growth into stationary phase is among the strongest inducers of the ESR, the ES

22 ntrations in soil solution by the soil-solid phase is an important process for providing plant root a

23 achieved for 463 of 487 features (95.1%) at phase I and 1220 of 1347 features (90.6%) at phase II.

24 ained for only two of 487 features (0.4%) at phase I and 19 of 1347 features (1.4%) at phase II.

25 ally weak for 232 of 302 features (76.8%) at phase I and 703 of 1075 features (65.4%) at phase II.

26 tion and posttransplant outcomes following a phase I and a phase III randomized trial.

27 Phase I and II clinical trials of NT3 (for constipation

28 However, phase I and II clinical trials with autologous and first

29 sed BTRs and to stepwise examine the role of Phase I and II enzymes (cytochrome P450 (CYP), uridine g

30 studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion

31 al of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report

32 tory criteria, suggesting that comparison of phase I and phase II titers could be reexamined as a sur

33 Data from phase I and phase II trials are already available for se

34 metry we identified 33 AMI metabolites (both Phase I and Phase II), occurring mostly in bile, liver a

35 n Examination Survey (NHANES) II, NHANES III Phase I and Phase II, and 1999-2016 continuous NHANES we

36 cognitive load by comparing the results from phase I and phase III.

37 nge indicated that boundary Theta(1) between phases I and II coincided with Psi at stomatal closure.

38 firm-level transaction records of the EU ETS Phases I and II, here we show that the participating fir

39 Unique identifier: NCT01175850 (IN.PACT SFA phase I) and NCT01566461 (IN.PACT SFA phase II).

40 Fifteen patients were recruited in phase I, and 9 mg/m(2) methotrexate was identified as th

41 95% CI 71.1-71.4, p < 0.001) reduction after phase I, and to 1.4% (95% CI 0.9-2.2) after phase II.

42 ttraction, the fluid dynamics of the cluster phase is arrested, leading to the formation of a colloid

43 ersion (9 to 13a) are biphasic, and the slow phase is ascribed to either direct cation 9 attack by ac

44 The crystallization of the planar phase is ascribed to the near-free-standing condition af

45 ngle DNAs, that acetylation of Smc3 during S phase is associated with J heads, and that sister DNAs a

46 inistrations (MDAs) per year over two years (phase I, August 2015-2017), followed by one year of reac

47 and autoinhibitory effects of fluoxetine on phase I biotransformation were analyzed.

48 However, transition from G(1) to S phase is blocked in the absence of Midkine-a, resulting

49 hydrogen phases: orientationally disordered Phase I; broken-symmetry Phase II and reentrant melt cur

50 bulk modulus of the high-pressure tetragonal phase is calculated to be 209(2) GPa and V(0) = 270(2) a

51 nomic and structural patterns in referral to phase I cancer trials in a case-control study design.

52 3/KHCO3 in the lower phase, HEP in the upper phase is capable of being regenerated from its sulfite/s

53 on from a disordered to a crystalline carpet phase is captured via spatial and temporal correlation f

54 anslational control targeting the initiation phase is central to the regulation of gene expression.

55 which a bilayer, resembling a liquid-ordered phase is changed into a bilayer resembling a fluid-liqui

56 The high-pressure phase is characterized by an extended network structure.

57 pen-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and s

58 The human PK properties from the Phase I clinical studies of 37 were better than anticipa

59 The purpose of this phase I clinical study was to test the effect of the TVB

60 e medial forebrain bundle (slMFB) in a small Phase I clinical study with a randomized-controlled onse

61 opment compound M8891, which is currently in phase I clinical testing in oncology patients.

62 safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebr

63 eport the results of a single-arm open-label phase I clinical trial designed to determine vaccine saf

64 we conducted an open-label, dose-escalation, Phase I clinical trial in liver transplantation.

65 The lead molecule entered a Phase I clinical trial in patients with solid tumors (NC

66 On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 we

67 A phase I clinical trial of the first generation ALK inhib

68 A phase I clinical trial showed that the combination of CB

69 ministering 1 to healthy human volunteers, a phase I clinical trial was conducted.

70 This phase I clinical trial was designed to evaluate whether

71 ucleases in subjects with stage IV PDAC in a phase I clinical trial.

72 2 is a novel anticancer thiosemicarbazone in phase I clinical trial.

73 -tolerated KRAS(G12C) inhibitor currently in phase I clinical trials (NCT03600883).

74 sing anticancer activity, CB-5083 failed its phase I clinical trials due to an unexpected off-target

75 Retrospective analysis of 2 phase I clinical trials investigating NIR-guided SLN map

76 It was further applied to two phase I clinical trials to evaluate potential biomarkers

77 cleotide-based therapies have been tested in phase I clinical trials, a quarter of which have reached

78 s (NYVAC-C) showed limited immunogenicity in phase I clinical trials.

79 g interaction (DDI) risk assessment in early phase I clinical trials.

80 KRAS(G12C) inhibitors(3,4) are in phase-I clinical trials and early data show partial resp

81 e design of drug-administration regimens for phase-I clinical trials.

82 ble domain structures of a large set of post-phase-I clinical-stage antibody therapeutics (CSTs) and

83 o such correlation in tumour biopsies from a Phase I cohort treated with NUC-1031.

84 ation programme until the cell proliferation phase is completed.

85 The mixing of the organic and aqueous phases is confined under a quasi-2D geometry.

86 In terms of thermodynamics, the aqueous phase is considered as a compressible fluid and its prop

87 tration of all tau variants in the condensed phase is constant.

88 As in S phase, global mobility in G1 phase is controlled by the DNA damage checkpoint and the

89 including both granular and continuous solid phases, is created for this end.

90 , the selectivity of the employed stationary phases is crucial.

91 est efficacy, an exploratory analysis of the phase I data showed a trend that PIK3CA-mutant patients

92 The first phase is defined by nonspecific medial and adventitial t

93 and that transitioning from mitosis into G1 phase is delayed in galectin-8-knockout HaCaT cells afte

94 rite arbitrary patterns of the ferromagnetic phase is demonstrated by local heating with a focused la

95 phase to the high-copper-mobility superionic phase is depressed.

96 With use of a standard 3 + 3 phase I design, patients received escalating doses of su

97 of single-crystalline ReS2 in a distorted 1T phase is determined at room temperature for the in-plane

98 rdly predictable and thereby the premonitory phase is difficult to catch, we scanned 9 patients daily

99 ategy to control the presence of the surface phase is discussed, using it as a tool in designing stra

100 , and proton transport properties of the CPP phase is discussed.

101 EV-101 is a phase I dose escalation/expansion study that enrolled pa

102 usly evaluated for the appropriate dose in a phase I dose-escalation study.

103 We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosiden

104 n transformation system resembling the human phase I drug-metabolizing system.

105 t periods >200 Myr, when they are broadly in phase (i.e. no time lag).

106 low temperature (<=200 degrees C) in aqueous phase (i.e., in a benign solvent), in which H(2)O served

107 Imaging at 30 s intervals revealed three phases (i.e., lag, exponential, and linear) in the devel

108 ic ultra-thin limit above which the wurtzite phase is energetically more favorable according to the t

109 rongly coupled occupied orbitals of opposite phase is enhanced.

110 of coordination cage immobilization on solid phases is envisaged to be applicable to the extensive li

111 ounds (SVOCs) between gas phase and particle phase is essential for exposure analysis and risk assess

112 Accurate copying of DNA during S phase is essential for genome stability and cell viabili

113 d how the specificity for being in different phases is established.

114 rop surrounded by an asphaltene-rich organic phase is exposed to a DC uniform electric field.

115 reated 20 patients with B-cell lymphoma on a phase I, first-in-human clinical trial of T cells expres

116 A methanol acceptor phase is flowed through a probe-mounted polydimethylsilo

117 tumor growth in which a rapid proliferative phase is followed by a regression phase (involution).

118 s observed, where an initial rapid oxidation phase is followed by a second slower reaction phase.

119 The healing phase is followed by the bone-remodeling phase.

120 The second phase is formed by gel-like assemblies of the disordered

121 The trigonal R-phase is formed from the cubic phase during cooling to r

122 y line between the solution phase and fibril phase is found by calculating the temperature-dependent

123 This phase is found to coexist with the nominal orthorhombic

124 se, while wall position in the other cardiac phases is found by image registration.

125 The 1T' phase is fully convertible into the semiconducting 2H ph

126 While for X = Tc the CI phase is further stabilized under tensile strain, for X

127 A small phase I GD2/GD3 vaccine trial (n = 15) described long-te

128 The ordered phase is generally identified based on the existence of

129 During phase I, grade 3 adverse events were anaemia (n=2), fati

130 , the formation of twin domains and impurity phases is hard to suppress, and the nucleation and growt

131 complexes retain native structure in the gas phase is highly dependent on experimental conditions.

132 resection and conventional radiotherapy in a phase I/Ib study.

133 In ongoing phase I, II and III clinical trials, enfortumab vedotin

134 ed chikungunya vaccine that shows promise in Phase I-II clinical trials.

135 e therapy cases and potentially for clinical phase I/II applications.

136 cross-platform R package for in silico drug phase I/II biotransformation prediction and mass-spectro

137 In the phase I/II CheckMate 358 study of virus-associated cance

138 The expansion cohort of the open-label, phase I/II CheckMate 436 study enrolled patients with co

139 This randomized phase I/II clinical study (n=60 healthy subjects aged 18

140 cance, these data have led to the start of a phase I/II clinical trial at our institution for newly d

141 SAFE-MILND (NCT01500304) is a multicenter, phase I/II clinical trial evaluating the safety and feas

142 ransplant Service Line is developing a novel phase I/II clinical trial with ex vivo expanded autologo

143 With Phase I/II clinical trials now underway using first-gene

144 se inhibitors of ATR and Wee1 are already in phase I/II clinical trials, this knowledge could soon be

145 Accordingly, CB-839 is currently in phase I/II clinical trials.

146 ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine t

147 T1113), RO1 CA136551-05, Alex Lemonade Stand Phase I/II Infrastructure Grant, Conquer Cancer Foundati

148 latinum-pretreated mUC were enrolled in this phase I/II multicenter study to receive NIVO3, NIVO3+IPI

149 This phase I/II prospective, open label, multicenter, randomi

150 We conducted 2 parallel phase I/II studies (ClinicalTrials.gov identifiers: NCT0

151 NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum toler

152 As part of a phase I/II study in patients with advanced/metastatic so

153 AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of

154 A dose escalation is planned in a subsequent phase I/II study to assess the therapeutic window of thi

155 We performed a prospective phase I/II study to evaluate the sst receptor antagonist

156 We conducted a phase I/II study to identify the optimal biologic dose (

157 This paradigm will be tested in a phase I/II TNBC clinical trial.

158 Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle

159 lity.METHODSWe report the early results of a phase I/II trial in B cell acute lymphoblastic leukemia

160 2b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age.

161 on tumor samples from patients enrolled in a Phase I/II trial of niraparib and pembrolizumab in ovari

162 We conducted a prospective phase I/II trial of noninvasive cardiac radioablation in

163 Moreover, good efficacy was seen in phase I/II trials of immune checkpoint inhibitors as mon

164 This phase I/II, single-center trial enrolled patients with m

165 We report on the outcome of a phase I/IIa clinical trial (EudraCT 2016-002053-38) with

166 XLRS who were considering participation in a phase I/IIa ocular gene therapy clinical trial at the Na

167 Conclusion: This phase I/IIa study provides safety data for (68)Ga-NeoBOM

168 that have been approved, that are undergoing phase I-III clinical trials or that show promise for the

169 mple degradation observed when the dispersed phase is in close proximity to the electrode surface.

170 Phase I: in 6 thigh muscle preparations, 2 energy settin

171 ially flooded with one phase before a second phase is injected via a flow-rate-controlled pump.

172 In Phase I, inspired by the proposed biosynthesis, epoxide-

173 Phase I interventions were associated with a significant

174 We find that the PGL-3 phase is intrinsically labile and requires a second phas

175 of the energy bands of the high-temperature phase is lifted in the low-temperature phase.

176 t at physiological temperatures, any ordered phase is likely to be absent or occupy a minimal interfa

177 This alternating EEG rhythm phase is likely to underlie the dissociative actions of

178 Access to metastable crystal phases is limited as their direct synthesis is challengi

179 At higher humidity, the resulting lamellar phase is maintained by partitioning excess water into is

180 ure, all-inorganic CsPbI(3) perovskite black phase is metastable relative to its yellow, nonperovskit

181 r (wt%) alloy strengthened with quasicrystal phase (I-Mg(3)Zn(6)Gd phase) is prepared through hot ext

182 s much more negative than predawn Psi during phase I (mild drought), reductions in midday Psi were mi

183 s that replicate in human cells; this second phase is modulated by breastfeeding.

184 The NO concentration within the emitted gas phase is monitored continuously with a commercial ampero

185 the photonic paramagnetic to photonic glass phase is more subtle in that the Parisi overlap function

186 stablished, the effect of chirality on these phases is much less studied.

187 ORTANCE Transition from latency to the lytic phase is necessary for herpesvirus-mediated pathology as

188 d intratracheally with C. burnetii Nine Mile phase I (NMI) and demonstrated susceptibility as determi

189 al distortions and demonstrate that the Cccm phase is non-metallic, with molecular H(2) units in the

190 This phase I, nonrandomized, open-label, dose-escalation (DE)

191 In conclusion, lag phase is not a reliable measure of stress because length

192 Mele SOC in monolayer graphene, the inverted phase is not expected to be a time-reversal-invariant to

193 pha-CsPbI(3) and orthorhombic gamma-CsPbI(3) phases) is not stable at room temperature, and it tends

194 A vapor/vapor-liquid phase is observed at hydrophobic and hydrophilic interfa

195 heric sporadic E layer with a downward tidal phase is observed followed by a subsequent intensificati

196 rich phase diagram with noncollinear twisted phases is obtained, and spin waves are further calculate

197 In phase I of our study, we analyzed simulations of a stand

198 A coherent rotational motion, the vortex phase, is of great interest because of its ability to or

199 the Aquilegia petal during the early phase (phase I) of spur development and also appears to be nece

200 In oscillatory systems, neuronal activity phase is often independent of network frequency.

201 The open-label phase is ongoing with no new enrolment, and current find

202 s complete, and follow-up of the maintenance phase is ongoing.

203 This Phase I open-label trial assessed the safety, efficacy i

204 Because only the black phase is optically active, this represents an impediment

205 In the phase I part of this study, patients were randomly assig

206 The later hyperinflammatory phase is partially MyD88 dependent and ineffective in th

207 f formalin-inactivated C. burnetii Nine Mile phase I (PIV) and phase II (PIIV) vaccines derived from

208 A phase I plasma pilot incorporated quantitative allele-sp

209 The third phase is poorly characterized biochemically, because pre

210 ose-limiting toxicities were observed in the phase I portion.

211 Entry into the stationary phase is preceded by a gradual, synchronized adaptation

212 ened with quasicrystal phase (I-Mg(3)Zn(6)Gd phase) is prepared through hot extrusion and subsequent

213 acute phase, and subsequently in the chronic phase is presented to guide preventive measures and impr

214 alysing binary phase diagrams to predict HEA phases is presented.

215 he observed enhanced adhesion in the nematic phase is primarily attributable to the increased interna

216 cterium-like particle (BLP).Methods: In this phase I, randomized, double-blind, placebo-controlled tr

217 We conducted a phase I, randomized, double-blind, placebo-controlled, d

218 This Phase I, randomized, observer-blind, placebo- and active

219 In a Phase I, randomized, partial double-blind, placebo-contr

220 cs/ATM/ATR: The checkpoint activated in G(2)-phase is regulated exclusively by ATR/CHK1; similarly at

221 The stability of the 9R phase is related to the existence of sessile Frank loops

222 thesize that the appearance of the different phases is related to the asymmetric structure of SMs and

223 e (DQC) phase, and body-centered cubic (BCC) phase, is reported.

224 athin CoSe nanoplates with tunable structure phases is reported.

225 osphorylation of TRF2 at Ser365 outside of S phase is required to release RTEL1 from telomeres, which

226 This productive phase is responsible for most herpesvirus-associated dis

227 asis participating in 2 different studies (a phase I risankizumab study and a phase II study of risan

228 A Phase I safety and pharmacokinetic study was conducted:

229 veloped in specific stages, where a widening phase is sandwiched between two lengthening phases.

230 ation of multiple SU-8 rods in the isotropic phase is shown.

231 This state, labelled here the 'harmonic phase', is shown to occur experimentally in spin ice, a

232 and chemical exchange between gas and liquid phases is shown to play an important role on the observe

233 lity of single cells in G(2)/M, but not G(1) phase, is significantly reduced by ARID1A inactivation.

234 ng superplastic deformation, the nanoscale I-phase is slightly elongated and the microstructure is st

235 Whereas the superionic phase is stable in the bulk only above ca. 100 degrees C

236 te phase and its relation to the martensitic phase is still an unresolved issue, even though it is cr

237 Phase I studies in pancreatic cancer (PDAC) utilizing P-

238 or currently under investigation in multiple phase I studies on various malignancies, and its clincal

239 Moreover, data from a phase I study led to the FDA granting breakthrough thera

240 uccessful preclinical imaging, a prospective phase I study of 10 patients with multiple myeloma was p

241 We conducted a phase I study of autologous T cells lentivirally-transdu

242 We conducted a first-in-humans phase I study of CTT1057 in patients with localized and

243 Patients and Methods This phase I study tested durvalumab doublets in parallel 3 +

244 Patients and Methods This phase I study tested the combination of M6620 and topote

245 These studies support the initiation of a phase I study to evaluate the safety and potential effic

246 The phase I study was aimed at evaluating the safety, biodis

247 A multicenter, open-label, repeated-dose, phase I study was conducted to assess the safety, tolera

248 Our phase I study with recombinant HCV E1/E2 envelope glycop

249 erable than twice-weekly dosages used in the phase I study, so 3 ug/kg every 2 weeks was the phase II

250 itide 3-kinase-delta,-gamma, in RR iNHL in a phase I study, the safety and efficacy of duvelisib mono

251 This phase I study, which to our knowledge is the first-in-hu

252 tructure search shows that the rocksalt-type phase is substantially metastable (>70 meV/atom) compare

253 At high pressure, rotation is hindered in Phase I, such that it cannot be regarded as a molecular

254 nly a few microliters of micellar extracting phase is sufficient for determination.

255 tural transition mechanism between 3R and 2H phases is tentatively proposed to be associated with the

256 Strengthening by precipitation of second phase is the guiding principle for the development of a

257 mation of this unique solid-liquid composite phase is the key to change the wetting behavior of the c

258 mise that lower hydrophobicity of the bonded phase is the key to enabling online nRPLC-MS analysis of

259 The chi phase is the most stable structure in the high-pressure/

260 Chromatography on chiral stationary phases is the standard method, but at a very high cost f

261 The implementation of Target: Stroke Phase I, the first stage of the American Heart Associati

262 The first phase is then rapidly displaced in the primary channel,

263 is more regulated in Phase II than it is in Phase I, thereby indicating that the Phase II is more ma

264 the coexistence of high- and low-temperature phases is thermodynamically impossible during a second-o

265 stallographic nature of the transitions from phase I to phases III and IV.

266 escribed here is a participant in an ongoing phase I trial (NCT00902044; active, not recruiting), and

267 server-blind, randomized, placebo-controlled phase I trial (NCT03300050), safety and immunogenicity o

268 This successful phase I trial also provides a possible avenue for achiev

269 Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personal

270 and young adult subjects participating in a Phase I trial of defined composition CD19CAR T cells (NC

271 , and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are curren

272 Here, we report a phase I trial using the Vaxxas HD-MAP to deliver a monov

273 ha-particle-emitting (211)At, we performed a phase I trial with intraperitoneal alpha-particle therap

274 against the allogeneic donor.METHODSIn this phase I trial, patients received either 1.5 x 106 MICs p

275 e-blind, placebo-controlled, dose-escalation Phase I trial.

276 ponse was determined within the context of a phase I trial.

277 emonstrated therapeutic potential in a prior phase I trial.

278 e systemic dose range considered safe in the Phase I trial.

279 s Perspectives, we highlight key elements of phase I trials and discuss how each one of them contribu

280 et routinely implemented in the setting of a phase I trials clinic.

281 For many years, oncology phase I trials have been referred to as 'toxicity trials

282 We performed two phase I trials of the histone deacetylase inhibitor vori

283 Our two phase I trials provide preliminary evidence supporting t

284 a novel treatment can be obtained in current phase I trials, which can therefore be considered to hav

285 esponse rates are increasingly reported from phase I trials.

286 turation in plagioclase as a single liquidus phase is triggered by their transcrustal ascent towards

287 show that the competition of these magnetic phases is tunable through applying either an external ma

288 esponse is coordinated with the reproductive phase is unclear.

289 n all Danish patients referred to the Danish Phase I Unit at Rigshospitalet from 2005 to 2016, and a

290 ified for patients with long distance to the Phase I Unit compared with short distance (adjusted odds

291 f socioeconomic position and distance to the Phase I Unit-and referral using a conditional logistic r

292 data on molecular hydrogen in its hexagonal phase I up to 123 GPa at room temperature.

293 a formalin-inactivated C. burnetii Nine Mile phase I vaccine (PIV) in beta(2)-microglobulin-deficient

294 The hydrophobicity of the bonded phase is varied, and the least hydrophobic bonded phase

295 Finally, we showed that the balance between Phase I versus Phase II SHM activities impacts the resul

296 Because an initial inflammatory phase is vital for tissue repair, we investigated the ro

297 tructure of graphene and graphene oxide (GO) phases is vitally important for any of its widespread in

298 The primary end point of phase I was to determine the OBD of methotrexate, and th

299 In phase I, we combined desk reviews, simulations, and focu

300 Finally, each respective phase is withdrawn into its respective pump.